|
|
|
|
|
|
|
11/12/06 |
|
|
GLOBALHealthPR Extends Global Reach |
|
|
|
|
 |
|
|
|
|
|
|
|
11th December 2006: GLOBALHealthPR has announced the addition of three new members, LBS Co. Ltd (LBS) of Japan, MHC Communication (MHC) of France and Noesis Comunicazione (Noesis) of Italy.
|
|
 |
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
|
|
|
|
|
|
|
16/09/06 |
|
|
European mental health groups unite to issue call to action on metabolics in mental health |
|
|
|
|
|
|
|
|
|
|
|
|
And leading clinicians name UNITE Survey a ‘wake up call to psychiatry’
PARIS, September 16th:
GAMIAN-Europe and EUFAMI today issued a call for action to address a growing crisis for people with mental illness – the relentless increase in CHD risk in this population. The statement followed presentation of the results of one of the largest ever global patient and carer surveys in psychiatry . It was echoed by demands for the clinical community to urgently address the physical health of their patients, by leading international clinicians who dubbed the results ‘staggering’.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10/08/06 |
|
|
Advate’s safety profile confirmed |
|
|
|
|
|
|
|
|
|
|
|
|
August 10th 2006 – The MHRA has announced the removal of Advate’s (Octocog Alfa Recombinant Coagulation Factor VIII) black triangle symbol, confirming its risk/benefit balance. The move marks the end of a period of detailed surveillance following the UK launch of Advate, the first and only haemophilia therapy without blood-based additives used for the prevention and control of bleeding episodes in people with haemophilia A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04/08/06 |
|
|
Introduction of new Advate convenience features |
|
|
|
|
|
|
|
|
|
|
|
|
COMPTON, England, 4th August 2006 - Baxter Healthcare Ltd announced today the introduction of BAXJECT II, an innovative needle-less reconstitution device and an improved packaging design for its plasma-albumin-free haemophilia A therapy ADVATE. Introduction of these two new convenience features has just started and patients will begin to receive them in the coming weeks. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18/05/06 |
|
|
Baxter and Jerini advance program to develop non-intravenous Hemophilia therapy |
|
|
|
|
|
|
|
|
|
|
|
|
Deerfield, Ill. and Berlin, Germany, May 18, 2006 – Baxter AG and Jerini AG today announced progress in their collaborative research program to develop a non-intravenous therapy for the treatment of hemophilia. Extensive in vitro and in vivo analysis has identified several synthetic lead molecules with promising pharmacological properties.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13/05/06 |
|
|
World Hypertension League calls for urgent action to get more hypertensive patients to Goal |
|
|
|
|
|
|
|
|
|
|
|
|
Survey identifies important gaps in clinical practice that must be addressed to ensure more patients reach blood pressure goal
13th May 2006: Despite major advances in cardiovascular medicine, nearly 60% of hypertension patients in the UK have blood pressure that is not controlled to the recommended goal, leaving them at risk of serious cardiovascular disease1. Today the results of a global survey have been announced that uncover significant gaps between current and recommended hypertension management and give valuable insight into physician awareness of the importance of blood pressure goal achievement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23/02/06 |
|
|
Preotact® a new Medicine to help in the fight against Osteoporosis is on the Way |
|
|
|
|
|
|
|
|
|
|
|
|
EU committee recommends that the Commission give EU marketing authorisation for a promising new osteoporosis drug from Nycomed. Preotact® strengthens and rebuilds bones enabling osteoporosis suffers a better chance of avoiding debilitating bone fractures.
Roskilde, 23 February 2006; Today, the treatment of osteoporosis took an important step forward when The European Committee for Medicinal Products for Human Use, CHMP, recommended the Commission to give Nycomed an EU marketing authorization for a promising new drug against “the silent disease”, osteoporosis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21/02/06 |
|
|
Santé Communications helping to Break the Sound Barrier |
|
|
|
|
|
|
|
|
|
|
|
|
London, 21st February 2006 – RNID, the largest charity for the UK’s nine million deaf and hard of hearing people, has appointed healthcare specialists Santé Communications to roll-out the regional arm of its high profile Breaking the Sound Barrier campaign. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19/01/06 |
|
|
ABPI Appoints Agency to Work on New Code of Practice Awareness Campaign |
|
|
|
|
|
|
|
|
|
|
|
|
The Association of the British Pharmaceutical Industry (ABPI) today announced plans to launch a major awareness campaign for the new Code of Practice. The ABPI has appointed Santé Communications, the specialist healthcare consultancy, to work on the campaign. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
